To prove a generic drug is as safe and effective as the branded version, pharmaceutical companies have to hand over upwards of 1,000 doses of the product to a generic developer. But if the manufacturer creating the generic drug cannot get its hands on enough sample, the development and testing process slows down. It could […]
Verily, Sanofi and other industry players team up with NIH to advance Parkinson’s therapies
The National Institutes of Health is joining forces with the tech and pharmaceutical industries to speed the development of new drugs for Parkinson’s disease and identify biomarkers for the debilitating condition. Companies participating in the public-private partnership include Celgene (NSDQ:CELG), GlaxoSmithKline (NYSE:GSK), The Michael J. Fox Foundation for Parkinson’s Research, Pfizer (NYSE:PFE), Sanofi (NYSE:SNY) and Verily. Combined the […]
Novocure misses sales, earnings estimates in Q2
Shares in Novocure (NSDQ:NVCR) fell today after the oncology company missed expectations on Wall Street with its second quarter results. The St. Helier, N.J.-based company reeled in its losses to -$21.2 million on sales of $38.4 million for the 3 months ended June 30, for bottom-line growth of 48% on sales growth of 114% compared with […]
Novocure brings Optune tech to drug trial for glioblastoma
Novocure (NSDQ:NVCR) said today that it joined a Phase Ib study to evaluate the safety of Celgene‘s (NSDQ:CELG) marizomib and temozolomide in combination with Optune for patients with newly-diagnosed glioblastoma. The trial is the first to assess Optune, the company’s “Tumor Treating Fields” delivery device, in combination with an investigational drug. Celgene and Triphase changed their ongoing […]
Leukemia trial to match patients with drugs based on genetic biomarkers
The Leukemia & Lymphoma Society said today that its expanding its Beat AML Master trial to include five investigational treatments for acute myeloid leukemia. The trial, which launched in October last year, has enrolled 70 patients and has garnered support by Alexion Pharmaceuticals (NSDQ:ALXN), Boehringer Ingelheim, Celgene (NSDQ:CELG) and Gilead Sciences (NSDQ:GILD), all of which are providing investigational […]
Celgene acquires Delinia, beats on Q4 earnings
Shares in Celgene (NSDQ:CELG) fell yesterday, even though the biopharmaceutical company beat earnings expectations on Wall Street with its 4th quarter results. The Summit, N.J.-based company posted profits of $1.29 million, or $1.61 per share, on sales of $2.9 million for the 3 months ended Dec. 31, for bottom-line growth of 34% on sales growth […]
Evotec, Celgene ink drug development deal for stem cell treatments for neurodegenerative diseases
Evotec (ETR:EVT) said today that it inked a 5-year drug discovery and development deal with Celgene (NSDQ:CELG) to identify stem cell therapies for a range of neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer’s disease and Parkinson’s disease. According to the agreement, Hamburg, Germany-based Evotec will receive an upfront payment of $45 million and Celgene will hold exclusive […]
